Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VS-6766 in KRAS- or BRAF-mutant NSCLC
2020-004265-39Phase 2Terminated
- Sponsor
- Verastem Oncology
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avutometinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Verastem Oncology. Primary endpoint: Safety and toxicity profile of VS-6766. Started Mar 2021; status: terminated.
02
Drugs
avutometinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004265-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004265-39.